Trial Profile

A Phase 2 clinical trial of SL-325 including in patients with autoimmune disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SL 325 (Primary)
Indications Autoimmune disorders
Focus Therapeutic Use

Most Recent Events

29 Sep 2025 New trial record
05 Aug 2025 According to Shattuck Labs Media Release, the total proceeds from the private placement (including full exercise of the accompanying common stock warrants), combined with current cash and cash equivalents, are expected to fund operations into 2029.
05 Aug 2025 According to Shattuck Labs Media Release, the trial is expected to occur in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com